Otsing

Teie tulemused

Näitab 6 / 6 tulemused

Health is a fundamental human right, and achieving equality in access to medicines is crucial for ensuring public health. The current system of innovation strongly relies on the private sector, while remuneration of innovation is mainly based on exclusivities. This system presents several issues, such as innovation being driven by market size, the partial misalignment between industry’s research and development (R&D) priorities and public health goals, access constraints, and the scarcity of disruptive ...

On 13 February 2019, Parliament and Council negotiators agreed on amending the EU rules on patent protection for generic and biosimilar medicines. Parliament is due to vote on the compromise text, approved by its Committee on Legal Affairs (JURI), at its second plenary session in April.

This report summarises the presentations and discussions at the Workshop on ‘Safer healthcare in Europe: improving patient safety and fighting antimicrobial resistance’, held at the European Parliament in Brussels, on Tuesday 24 February 2015. The aim of the workshop was to discuss the main challenges and future perspectives related to the topic of patient safety and the threat of antimicrobial resistance in Europe. The workshop was hosted by MEP Piernicola PEDICINI, ENVI Committee Rapporteur for ...

Despite long-running negotiations, there appears little prospect that the EU-India Bilateral Trade and Investment Agreement will be signed in 2014. Pending such an agreement, EU-India trade relations are regulated under their WTO commitments. Several recent disputes between India and the EU at WTO level illustrate the difficulties faced in the trading relationship.

Uuringus antakse ülevaade ravimihindade erinevuste kohta liikmesriikides. Analüüsitakse patendiga kaitstud ravimite ja patendita ravimite hindu, millega konkureerivad nendest odavamad geneerilised variandid. Tuuakse välja meetodid, mida liikmesriigid on kasutanud ravimituru reguleerimiseks nii pakkumise kui ka nõudluse poolel ning hinnatakse nende erinevate meetodite mõju ravimihindadele, kulude ohjamisele ja tööstuse innovatsioonile. Samuti arutletakse põhjuste üle, mis mõjutavad patsientide juurdepääsu ...

The study examines the the draft Regulation establishing a compulsory licensing system for the export of patented drugs to developing countries. The Regulation aims at uniformly implementing, within the European Union, the Decision of the WTO of 30 August 2003 on the TRIPS Agreement and Public Health. Following the presentation of the core aspects of the draft Regulation, the paper outlines the possible impacts of the Regulation, including the difficulties faced by importing countries. The paper ...